Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4194) 4194
Publication (629) 629
Newspaper Article (73) 73
Book Review (46) 46
Newsletter (36) 36
Book Chapter (20) 20
Magazine Article (17) 17
Data Set (2) 2
Trade Publication Article (2) 2
Transcript (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3527) 3527
tenofovir (3046) 3046
index medicus (2636) 2636
female (1890) 1890
hiv infections - drug therapy (1845) 1845
male (1779) 1779
adenine - analogs & derivatives (1774) 1774
adult (1562) 1562
anti-hiv agents - therapeutic use (1512) 1512
adenine - therapeutic use (1442) 1442
infectious diseases (1401) 1401
hiv (1229) 1229
organophosphonates - therapeutic use (1227) 1227
middle aged (1191) 1191
pharmacology & pharmacy (998) 998
antiviral agents - therapeutic use (918) 918
tenofovir disoproxil fumarate (866) 866
emtricitabine (810) 810
treatment outcome (770) 770
lamivudine (758) 758
hepatitis b, chronic - drug therapy (741) 741
immunology (726) 726
human immunodeficiency virus--hiv (693) 693
antiviral agents (687) 687
antiretroviral therapy (684) 684
hepatitis b (681) 681
drug therapy (646) 646
drug therapy, combination (640) 640
virology (590) 590
viral load (588) 588
hiv infection (578) 578
anti-hiv agents - adverse effects (555) 555
therapy (555) 555
lamivudine - therapeutic use (546) 546
anti-hiv agents - administration & dosage (544) 544
reverse transcriptase inhibitors - therapeutic use (543) 543
gastroenterology & hepatology (542) 542
tenofovir - therapeutic use (522) 522
health aspects (520) 520
hiv infections - virology (517) 517
infection (512) 512
hiv infections - prevention & control (493) 493
deoxycytidine - analogs & derivatives (474) 474
adenine - administration & dosage (469) 469
hiv-1 - drug effects (464) 464
microbiology (464) 464
adenine - adverse effects (440) 440
antiretroviral drugs (432) 432
prevention (413) 413
young adult (413) 413
organophosphonates - administration & dosage (403) 403
deoxycytidine - therapeutic use (399) 399
drug resistance, viral (384) 384
hiv infections - complications (384) 384
hepatitis (379) 379
organophosphonates - adverse effects (379) 379
risk factors (377) 377
analysis (375) 375
care and treatment (374) 374
virus diseases (370) 370
safety (369) 369
research (368) 368
hepatitis b virus (366) 366
aids/hiv (356) 356
dosage and administration (349) 349
highly active antiretroviral therapy (349) 349
aids (338) 338
guanine - analogs & derivatives (338) 338
disoproxil fumarate (336) 336
entecavir (335) 335
efavirenz (326) 326
cd4 lymphocyte count (325) 325
adefovir dipivoxil (321) 321
pharmacokinetics (319) 319
drug combinations (318) 318
human-immunodeficiency-virus (317) 317
aged (311) 311
antiretroviral therapy, highly active (309) 309
efficacy (308) 308
retrospective studies (308) 308
adolescent (306) 306
drug resistance (305) 305
hiv-1 (300) 300
infections (300) 300
animals (299) 299
article (297) 297
guanine - therapeutic use (293) 293
hepatitis b virus - drug effects (293) 293
acquired immune deficiency syndrome--aids (290) 290
clinical trials (279) 279
hepatitis b virus - genetics (279) 279
mutation (276) 276
patients (275) 275
double-blind (263) 263
medicine (261) 261
resistance (249) 249
hiv-1 - genetics (248) 248
human immunodeficiency virus (246) 246
hiv-infected patients (242) 242
research article (238) 238
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4181) 4181
Spanish (51) 51
French (36) 36
German (32) 32
Chinese (10) 10
Hungarian (7) 7
Japanese (6) 6
Turkish (3) 3
Italian (2) 2
Korean (2) 2
Polish (2) 2
Russian (2) 2
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
by Razonable, Raymund R., MD
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
Abstract Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
by Perez-Molina, José A, PhD and Rubio, Rafael, PhD and Rivero, Antonio, PhD and Pasquau, Juan, MD and Suárez-Lozano, Ignacio, MD and Riera, Melcior, MD and Estébanez, Miriam, PhD and Santos, Jesús, PhD and Sanz-Moreno, José, PhD and Troya, Jesús, MD and Mariño, Ana, MD and Antela, Antonio, PhD and Navarro, Jordi, MD and Esteban, Herminia, BSB and Moreno, Santiago, PhD and GESIDA 7011 Study Grp and GESIDA 7011 Study Group
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1—Infected Patients: Week 48 Results
by Joel E. Gallant and Ellen Koenig and Jaime Andrade-Villanueva and Ploenchan Chetchotisakd and Edwin DeJesus and Francisco Antunes and Keikawus Arastéh and Graeme Moyle and Giuliano Rizzardini and Jan Fehr and Yapei Liu and Lijie Zhong and Christian Callebaut and Javier Szwarcberg and Martin S. Rhee and Andrew K. Cheng
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
by Cohen, Calvin J, Dr and Andrade-Villanueva, Jaime, Prof and Clotet, Bonaventura, MD and Fourie, Jan, MD and Johnson, Margaret A, Prof and Ruxrungtham, Kiat, Prof and Wu, Hao, MD and Zorrilla, Carmen, MD and Crauwels, Herta, PhD and Rimsky, Laurence T, PhD and Vanveggel, Simon, MSc and Boven, Katia, MD and THRIVE Study Grp and THRIVE study group
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
by Naggie, Susanna and Sulkowski, Mark S
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: A Randomized, controlled equivalence trial
by Lennox, Jeffrey L and Landovitz, Raphael J and Ribaudo, Heather J and Ofotokun, Ighovwerha and Na, Lumine H and Godfrey, Catherine and Kuritzkes, Daniel R and Sagar, Manish and Brown, Todd T and Cohn, Susan E and McComsey, Grace A and Aweeka, Francesca and Fichtenbaum, Carl J and Presti, Rachel M and Koletar, Susan L and Haas, David W and Patterson, Kristine B and Benson, Constance A and Baugh, Bryan P and Leavitt, Randi Y and Rooney, James F and Seekins, Daniel and Currier, Judith S and ACTG A5257 Team
Annals of Internal Medicine, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 471
Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. To evaluate 3... 
Darunavir | Humans | Male | Viral Load | Oligopeptides - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | HIV-1 - isolation & purification | Atazanavir Sulfate | Adult | Female | Drug Therapy, Combination | RNA, Viral - isolation & purification | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | HIV-1 - genetics | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Reverse Transcriptase Inhibitors | Deoxycytidine - analogs & derivatives | Drug Combinations | Therapeutic Equivalency | Reverse transcriptase inhibitors | Dosage and administration | Research | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
by Quarraisha Abdool Karim and Salim S. Abdool Karim and Janet A. Frohlich and Anneke C. Grobler and Cheryl Baxter and Leila E. Mansoor and Ayesha B. M. Kharsany and Sengeziwe Sibeko and Koleka P. Mlisana and Zaheen Omar and Tanuja N. Gengiah and Silvia Maarschalk and Natasha Arulappan and Mukelisiwe Mlotshwa and Lynn Morris and Douglas Taylor and CAPRISA 004 Trial Grp and CAPRISA 004 Trial Group and on behalf of the CAPRISA 004 Trial Group
Science, ISSN 0036-8075, 9/2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | VAGINAL GEL | INDIVIDUALS | SOUTH-AFRICA | PROPHYLAXIS | IN-VITRO | TRANSMISSION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | MALE CIRCUMCISION | RANDOMIZED CONTROLLED-TRIAL | CHALLENGES | HIV Infections - prevention & control | Anti-Infective Agents, Local - therapeutic use | Urban Population - statistics & numerical data | HIV Infections - epidemiology | Humans | Anti-Infective Agents, Local - adverse effects | Drug Resistance, Viral | Administration, Intravaginal | Viral Load | Incidence | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Adenine - adverse effects | HIV-1 - physiology | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Vaginal Creams, Foams, and Jellies | Rural Population - statistics & numerical data | Sexual Behavior | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | South Africa - epidemiology | Organophosphonates - adverse effects | Adenine - administration & dosage | Pregnancy | Organophosphonates - administration & dosage | Anti-Infective Agents, Local - administration & dosage | Adolescent | Patient Compliance | Pregnancy Outcome | Prevention | Anti-infective agents | Research | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results
by Rockstroh, Jürgen K and Dejesus, Edwin and Henry, Keith and Molina, Jean-Michel and Gathe, Joseph and Ramanathan, Srinivasan and Wei, Xuelian and Plummer, Andrew and Abram, Michael and Cheng, Andrew K and Fordyce, Marshall W and Szwarcberg, Javier and GS-236-0103 Study Team
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
This ongoing, randomized, double-blind, active-controlled phase 3 international trial demonstrated the noninferior efficacy of... 
Emtricitabine | Tenofovir | Treatment-naive | HIV | Elvitegravir | Efavirenz | Antiretroviral therapy | Cobicistat | emtricitabine | treatment-naive | INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | tenofovir | SAFETY | antiretroviral therapy | elvitegravir | PHASE-3 | IMMUNOLOGY | cobicistat | RILPIVIRINE | efavirenz | Confidence Intervals | Humans | Male | RNA, Viral - blood | Alanine Transaminase - blood | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Deoxycytidine - therapeutic use | Adenine - therapeutic use | HIV-1 - isolation & purification | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Pyridines - therapeutic use | HIV Infections - blood | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV Infections - virology | HIV-1 - genetics | Bilirubin - blood | Bone Density - drug effects | Aspartate Aminotransferases - blood | Triglycerides - blood | Creatinine - blood | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
by Arribas, Jose R, Dr and Pialoux, Gilles, Prof and Gathe, Joseph, MD and Di Perri, Giovanni, Prof and Reynes, Jacques, Prof and Tebas, Pablo, MD and Nguyen, Thai, MD and Ebrahimi, Ramin, MS and White, Kirsten, PhD and Piontkowsky, David, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Summary Background Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency. We aimed... 
Infectious Disease | INFECTIOUS DISEASES | DISOPROXIL FUMARATE | EFAVIRENZ | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | INITIAL TREATMENT | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | SINGLE-TABLET REGIMEN | ADHERENCE | HAART | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights